ITEM VIEW

A multi-parameter approach for predicting prostate cancer

dc.contributor.authorSerafin, Antonioen_ZA
dc.contributor.authorChinhengo, Angelaen_ZA
dc.contributor.authorFernandez, Pedroen_ZA
dc.contributor.authorAkudugu, Johnen_ZA
dc.date.accessioned2018-08-15T10:32:04Z
dc.date.available2018-08-15T10:32:04Z
dc.date.issued2017
dc.identifier.citationSerafin, A., et al. 2017. A multi-parameter approach for predicting prostate cancer. Cogent Medicine, 4:1329257, doi:10.1080/2331205X.2017.1329257
dc.identifier.issn2331-205X (online)
dc.identifier.otherdoi:10.1080/2331205X.2017.1329257
dc.identifier.urihttp://hdl.handle.net/10019.1/104270
dc.descriptionCITATION: Serafin, A., et al. 2017. A multi-parameter approach for predicting prostate cancer. Cogent Medicine, 4:1329257, doi:10.1080/2331205X.2017.1329257.
dc.descriptionThe original publication is available at https://www.cogentoa.com
dc.description.abstractUrokinase plasminogen activator (uPA) and its inhibitor (PAI-1) have shown to be of merit as biomarkers for a variety of cancers. The objective of this project was to assay for uPA and PAI-1 in prostate needle biopsy tissue from 217 patients using the FEMTELLE enzyme linked immunosorbent (ELISA) assay, and to examine the robustness of PAI-1 as a candidate marker in benign prostatic hyperplasia (BPH) and prostate cancer (PCa), as previously identified in a different cohort of 111 patients. These results validate the assertion that PAI-1 levels of >4.5 ng mg−1 protein in prostate biopsies are indicative of prostate malignancy in elderly men, but further show that tissue from BPH patients in the 70–80 year age interval express significantly high levels of this marker. To address this anomaly, a malignancy index, derived from the concentrations of prostate-specific antigen (PSA), uPA, and PAI-1, and patient age is proposed. This simple index discriminates prostate tissue from BPH and PCa patients with concordance indices of 0.59 and 0.69 when tissues are taken as biopsy or transurethral resection of the prostate (TURP), respectively. Corresponding indices for PSA as a predictor of prostate disease were 0.67 and 0.73. Further evaluation of the proposed malignancy index using specimens, such as venous blood, could prove valuable in the search for non-invasive predictive assays.en_ZA
dc.description.urihttps://www.cogentoa.com/article/10.1080/2331205X.2017.1329257
dc.format.extent9 pages ; illustration
dc.language.isoen_ZAen_ZA
dc.publisherCogent OA
dc.subjectProstate -- Cancer -- Diagnosisen_ZA
dc.titleA multi-parameter approach for predicting prostate canceren_ZA
dc.typeArticleen_ZA
dc.description.versionPublisher's version
dc.description.versionPublisher's version
dc.description.versionAuthors retain copyright


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW